Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme

Materials
L NamE Ruiz-Hernández

Abstract

Glioblastoma multiforme is one of the most prevalent and malignant forms of central nervous system tumors. The treatment of glioblastoma remains a great challenge due to its location in the intracranial space and the presence of the blood⁻brain tumor barrier. There is an urgent need to develop novel therapy approaches for this tumor, to improve the clinical outcomes, and to reduce the rate of recurrence and adverse effects associated with present options. The formulation of therapeutic agents in nanostructures is one of the most promising approaches to treat glioblastoma due to the increased availability at the target site, and the possibility to co-deliver a range of drugs and diagnostic agents. Moreover, the local administration of nanostructures presents significant additional advantages, since it overcomes blood⁻brain barrier penetration issues to reach higher concentrations of therapeutic agents in the tumor area with minimal side effects. In this paper, we aim to review the attempts to develop nanostructures as local drug delivery systems able to deliver multiple agents for both therapeutic and diagnostic functions for the management of glioblastoma.

References

May 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·S K HobbsR K Jain
Nov 1, 2001·Topics in Magnetic Resonance Imaging : TMRI·V M RungeJ R Jinkins
Jan 5, 2002·Journal of Neuro-oncology·A BoiardiA Silvani
Jun 14, 2002·Journal of Neuro-oncology·Phillip B StormJon Weingart
Sep 26, 2002·Journal of Vascular Research·Bengt RippeDaniele Venturoli
Oct 18, 2002·Advanced Drug Delivery Reviews·Paul P WangHenry Brem
Mar 28, 2003·Neoplasia : an International Journal for Oncology Research·Samuel J HassenbuschDennis Pietronigro
Nov 1, 1964·Archives of Neurology·C B WILSON
Oct 14, 2003·Drug Discovery Today·David E Clark
Mar 5, 2004·International Journal of Cancer. Journal International Du Cancer·Sebastian C J SteinigerSvetlana E Gelperina
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sandrine OstermannRoger Stupp
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 19, 2005·Radiology·Fumiyuki YamasakiMuhamad A Thohar
Nov 24, 2005·International Journal of Pharmaceutics·Donald E Owens, Nicholas A Peppas
Nov 30, 2005·Journal of Neuro-oncology·Andreas JordanRoland Felix
Jul 10, 2007·Acta Neuropathologica·David N LouisPaul Kleihues
Sep 22, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Grace Y KimMichael J Cima
Feb 1, 2008·Journal of Medicinal Chemistry·M Paul Gleeson
Aug 30, 2008·The AAPS Journal·Françoise HervéJean-Michel Scherrmann
Dec 10, 2008·CNS Drugs·Mayur M PatelAvani F Amin
Sep 8, 2009·Expert Opinion on Drug Delivery·Valentino LaquintanaGiuseppe Trapani
Dec 22, 2009·Journal of Neurosurgery·John H SampsonUNKNOWN PRECISE Trial Investigators
Jan 9, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Changyou ZhanWeiyue Lu
Mar 11, 2010·Handbook of Experimental Pharmacology·Vladimir P Torchilin
May 1, 2010·Drug Delivery·Raquel De SouzaMicheline Piquette-Miller
Jul 10, 2010·Nature Reviews. Drug Discovery·Robby A Petros, Joseph M DeSimone
Oct 19, 2010·International Journal of Pharmaceutics·Yasemin CırpanlıJean-Pierre Benoit
May 7, 2011·Accounts of Chemical Research·Twan LammersFabian Kiessling
May 18, 2011·Interdisciplinary Toxicology·Svorad StolcIvica Kukurová
Jun 7, 2011·International Journal of Pharmaceutics·Stefanie WohlfartJörg Kreuter

❮ Previous
Next ❯

Citations

Jul 30, 2019·Small·Christina M MarvinDavid S Lawrence
Jun 7, 2019·International Journal of Molecular Sciences·Monica FedeleGuidalberto Manfioletti
Dec 5, 2019·Frontiers in Bioengineering and Biotechnology·Michele d'AngeloAnnamaria Cimini
Sep 17, 2020·Biomedicines·Lavinia SalamaShaker A Mousa
Jan 28, 2020·Journal of Chemotherapy·Vahid RezaeiFarzaneh Khademi
Dec 6, 2019·Frontiers in Bioengineering and Biotechnology·Andrei BelousovVadim Kumeiko
Jan 25, 2021·Advanced Drug Delivery Reviews·Taskeen Iqbal JanjuaAmirali Popat
Dec 4, 2019·Advanced Drug Delivery Reviews·Rucha PanditJürgen Götz
Feb 9, 2021·Expert Review of Clinical Pharmacology·Yadollah OmidiHossein Omidian
Dec 17, 2020·Pharmaceutics·Sathishbabu ParanthamanDevegowda Vishakante Gowda
Feb 21, 2021·Drug Discovery Today·Shreya PawarArun K Iyer
Mar 9, 2021·Frontiers in Oncology·Monserrat Llaguno-MunivePatricia Garcia-Lopez
Sep 9, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Gi Doo ChaDae-Hyeong Kim
Mar 23, 2021·Journal of Drug Targeting·Yuan GaoAnchang Liu
Feb 15, 2021·PM & R : the Journal of Injury, Function, and Rehabilitation·Nasim ChowdhuryMichael W O'Dell
Jul 3, 2021·International Journal of Molecular Sciences·Maya A DymovaVladimir A Richter
May 22, 2020·ACS Medicinal Chemistry Letters·Alessio MolinariMaurizio Botta

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotide
xenografts
xenograft
transfection
imaging techniques

Software Mentioned

Gliadel

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.